Patents by Inventor David Marcoux
David Marcoux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11701373Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: GrantFiled: May 4, 2021Date of Patent: July 18, 2023Assignee: Bristol-Myers Squibb CompanyInventors: Alaric J. Dyckman, T. G. Murali Dhar, Hai-Yun Xiao, John L. Gilmore, Michael G. Yang, Zili Xiao, David Marcoux
-
Publication number: 20220331346Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: ApplicationFiled: May 4, 2021Publication date: October 20, 2022Inventors: Alaric J. DYCKMAN, T.G. Murali Dhar, Hai-Yun Xiao, John L. Gilmore, Michael G. Yang, Zili Xiao, David Marcoux
-
Patent number: 11332442Abstract: The invention generally relates to a process for preparing compounds, including Compound of Formula (I), useful as key intermediates in the preparation of compounds having ROR?t antagonist properties.Type: GrantFiled: August 12, 2020Date of Patent: May 17, 2022Assignees: Bristol-Myers Squibb Company, Syngene International LimitedInventors: William P. Gallagher, John Ryan Coombs, Carlos A. Guerrero, David Marcoux, Qing Shi, Candice Lee Joe, Sanjeewa Rupasinghe, Jason J. Zhu, Srinivas Kalidindi, Sathasivam Shunmugaraj, Moorthy Kandasamy, Siva Sankar Bondigela, Rajappa Vaidyanathan, Shankar Tulsidas Tendulkar, Sankar Kuppusamy, Francisco González-Bobes
-
Publication number: 20220048859Abstract: The invention generally relates to a process for preparing compounds, including Compound of Formula (I), useful as key intermediates in the preparation of compounds having ROR?t antagonist properties.Type: ApplicationFiled: August 12, 2020Publication date: February 17, 2022Inventors: William P. Gallagher, John Ryan Coombs, Carlos A. Guerrero, David Marcoux, Qing Shi, Candice Lee Joe, Sanjeewa Rupasinghe, Jason J. Zhu, Srinivas Kalidindi, Sathasivam Shunmugaraj, Moorthy Kandasamy, Siva Sankar Bondigela, Rajappa Vaidyanathan, Shankar Tulsidas Tendulkar, Sankar Kuppusamy, Francisco González-Bobes
-
Patent number: 11058696Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: GrantFiled: May 21, 2020Date of Patent: July 13, 2021Assignee: Bristol-Myers Squibb CompanyInventors: Alaric J. Dyckman, T. G. Murali Dhar, Hai-Yun Xiao, John L. Gilmore, Michael G. Yang, Zili Xiao, David Marcoux
-
Publication number: 20200281952Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: ApplicationFiled: May 21, 2020Publication date: September 10, 2020Inventors: Alaric J. Dyckman, T.G. Murali Dhar, Hai-Yun Xiao, John L. Gilmore, Michael G. Yang, Zili Xiao, David Marcoux
-
Patent number: 10711020Abstract: There are described ROR? modulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: GrantFiled: March 7, 2019Date of Patent: July 14, 2020Assignee: Bristol-Myers Squibb CompanyInventors: Jingwu Duan, T. G. Murali Dhar, David Marcoux, Robert J. Cherney
-
Patent number: 10709719Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: GrantFiled: November 13, 2018Date of Patent: July 14, 2020Assignee: Bristol-Myers Squibb CompanyInventors: Alaric J. Dyckman, T. G. Murali Dhar, Hai-Yun Xiao, John L. Gilmore, Michael G. Yang, Zili Xiao, David Marcoux
-
Patent number: 10633354Abstract: Disclosed are compounds of Formula (I), Formula (II), Formula (III), and Formula (IV) or salts thereof, wherein R2 is —OH or —OP(O)(OH)2; and R1 is defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: GrantFiled: August 31, 2017Date of Patent: April 28, 2020Assignee: Bristol-Myers Squibb CompanyInventors: David Marcoux, Hai-Yun Xiao, T. G. Murali Dhar, Alaric J. Dyckman
-
Patent number: 10435369Abstract: There are described ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: GrantFiled: November 8, 2017Date of Patent: October 8, 2019Assignee: Bristol-Myers Squibb CompanyInventors: David Marcoux, Myra Beaudoin Bertrand, T. G. Murali Dhar, Michael G. Yang, Zili Xiao, Hai-Yun Xiao, Yeheng Zhu, Carolyn A. Weigelt, Douglas G. Batt
-
Publication number: 20190241588Abstract: There are described ROR? modulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: ApplicationFiled: March 7, 2019Publication date: August 8, 2019Inventors: Jingwu DUAN, T.G. Murali Dhar, David Marcoux, Robert J. Cherney
-
Publication number: 20190218193Abstract: Disclosed are compounds of Formula (I), Formula (II), Formula (III), and Formula (IV) or salts thereof, wherein R2 is —OH or —OP(O)(OH)2; and R1 is defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: ApplicationFiled: August 31, 2017Publication date: July 18, 2019Inventors: David Marcoux, Hai-Yun Xiao, T.G. Murali Dhar, Alaric J. Dyckman
-
Patent number: 10273259Abstract: There are described ROR? modulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: GrantFiled: September 12, 2017Date of Patent: April 30, 2019Assignee: Bristol-Myers Squibb CompanyInventors: Jingwu Duan, T. G. Murali Dhar, David Marcoux, Robert J. Cherney
-
Publication number: 20190076450Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: ApplicationFiled: November 13, 2018Publication date: March 14, 2019Inventors: Alaric J. Dyckman, T.G. Murali Dhar, Hai-Yun Xiao, John L. Gilmore, Michael G. Yang, Zili Xiao, David Marcoux
-
Patent number: 10214537Abstract: Disclosed are compounds of Formula (I) or a salt thereof; wherein: X is N or CH; Q1 is: (i) Cl, Br, I, —CN, —CH3, or —CF3; (ii) a 5-membered heteroaryl selected from pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, and thiadiazolyl; (iii) a 6?membered heteroaryl selected from pyridinyl, pyridazinyl, and pyrimidinyl; or (iv) a bicyclic heteroaryl selected from indolyl, pyrrolopyridinyl, pyrazolopyridinyl and benzo[d]oxazolyl; wherein each of said 5-membered, 6-membered, and bicyclic heteroaryl is substituted with zero to 1 Ra and zero to 1 Rb; and R1, R2, R3, R4, R5, R6, Ra, and Rb are defined herein. Also disclosed are methods of using such compounds as modulators of PI3K, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.Type: GrantFiled: October 21, 2015Date of Patent: February 26, 2019Assignee: Bristol-Myers Squibb CompanyInventors: Rajeev S. Bhide, Douglas G. Batt, Robert J. Cherney, Lyndon A. M. Cornelius, Qingjie Liu, David Marcoux, James Neels, Michael A. Poss, Zheming Ruan, Qing Shi, Anurag S. Srivastava, Lan-ying Qin, Joseph A. Tino, Scott Hunter Watterson
-
Patent number: 10166249Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: GrantFiled: July 12, 2017Date of Patent: January 1, 2019Assignee: Bristol-Myers Squibb CompanyInventors: Alaric J. Dyckman, T. G. Murali Dhar, Hai-Yun Xiao, John L. Gilmore, Michael G. Yang, Zili Xiao, David Marcoux
-
Patent number: 10023576Abstract: Disclosed are compounds of Formula (I); or a salt thereof; wherein Qi is (i) Cl, Br, I, —CN, —CH3, or —CF3; or (ii) pyrazole, triazole, or pyridinyl, each substituted with R1; Q2 is pyridinyl, indazolyl, isoquinolinyl, or benzo[d]imidazolyl substituted with R2 and R3; and R1, R2, and R3 are defined herein. Also disclosed are methods of using such compounds as modulators of PI3K, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.Type: GrantFiled: October 21, 2015Date of Patent: July 17, 2018Assignee: Bristol-Myers Squibb CompanyInventors: Rajeev S. Bhide, Zheming Ruan, Robert J. Cherney, Lyndon A. M. Cornelius, T. G. Murali Dhar, Hua Gong, David Marcoux, Michael A. Poss, Lan-ying Qin, Qing Shi, Joseph A. Tino
-
Publication number: 20180127368Abstract: There are described ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: ApplicationFiled: November 8, 2017Publication date: May 10, 2018Inventors: David Marcoux, Myra Beaudoin Bertrand, T.G. Murali Dhar, Michael G. Yang, Zili Xiao, Hai-Yun Xiao, Yeheng Zhu, Carolyn A. Weigelt, Douglas G Batt
-
Publication number: 20180002358Abstract: There are described ROR? modulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: ApplicationFiled: September 12, 2017Publication date: January 4, 2018Inventors: Jingwu Duan, T.G. Murali Dhar, David Marcoux, Qing Shi, Douglas G. Batt, Qingjie Liu, Robert J. Cherney, Lyndon A.M. Cornelius, Anurag S. Srivastava, Myra Beaudoin Bertrand, Carolyn A. Weigelt
-
Publication number: 20170355698Abstract: Disclosed are compounds of Formula (I); or a salt thereof; wherein Qi is (i) Cl, Br, I, —CN, —CH3, or —CF3; or (ii) pyrazole, triazole, or pyridinyl, each substituted with R1; Q2 is pyridinyl, indazolyl, isoquinolinyl, or benzo[d]imidazolyl substituted with R2 and R3; and R1, R2, and R3 are defined herein. Also disclosed are methods of using such compounds as modulators of PI3K, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.Type: ApplicationFiled: October 21, 2015Publication date: December 14, 2017Inventors: Rajeev S. Bhide, Zheming Ruan, Robert J. Cherney, Lyndon A.M. Cornelius, T.G.Murali Dhar, Hua Gong, David Marcoux, Michael A. Poss, Lan-ying Qin, Qing Shi, Joseph A. Tino